T. Rowe Price Associates
GEN

T. Rowe Price Associates’s Genesis Healthcare, Inc. GEN Stock Holding History

T. Rowe Price Associates’s Portfolio GEN Stock Details GEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,230
Closed -$10K – 2562
2020
Q1 		$10K Buy
12,230
+800
+7% +$1.14K ﹤0.01% 2501
2019
Q4 		$19K Buy
+11,430
New +$17.2K ﹤0.01% 2514

Other funds holding GEN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
V3 Capital Management Dallas, Texas $33.4M AUM 5.9% 1-Year Est. Return
FWC
First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

T. Rowe Price Associates's GEN Position: Q2 2020 in Review

T. Rowe Price Associates sold out of Genesis Healthcare, Inc. (GEN) in Q2 2020, closing a stake of 12,230 shares — an estimated $10K sold.

T. Rowe Price Associates first reported a position in GEN in Q4 2019 and held it in 2 quarters. The position peaked at $19K in Q4 2019. 58 funds tracked by Wall St. Rank hold GEN as of Q2 2020.

  • T. Rowe Price Associates reported no remaining Genesis Healthcare, Inc. position as of Q2 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 12,230 Genesis Healthcare, Inc. shares in Q2 2020, an estimated $10K.
  • T. Rowe Price Associates first reported a position in Genesis Healthcare, Inc. in Q4 2019 and held it in 2 quarters.
  • T. Rowe Price Associates's Genesis Healthcare, Inc. position peaked at $19K in Q4 2019.
  • 58 funds tracked by Wall St. Rank held Genesis Healthcare, Inc. as of Q2 2020.

Based on T. Rowe Price Associates's 13F filing for Q2 2020, filed 14 Aug 2020.